Phase 2Recruiting
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (PrisMN)
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)
- Sponsor
- Climb Bio, Inc. (Industry)
- Enrolment
- 45 planned
- Conditions
- Primary Membranous Nephropathy
- Interventions
- budoprutug
- Ages
- adults, older adults
- Registry
- NCT07096843
Full record on ClinicalTrials.gov
From the registry
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Primary outcomes
- Incidence of Treatment-Emergent Adverse Events (TEAEs)
History
Primary completion expected
Last registry update
Started
Registered